Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems

NCT06959277 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. The main question it aims to answer is whether participants who use Walkasins on an everyday basis over a six-month period will report better awareness of their foot placement on the ground. Researchers will compare Walkasins users to a control group of participants who are not using Walkasins to see if the device improves the users' performance on some standing and walking tests. Control group participants will get Walkasins after six months of being in the study. During the study participants will be asked to do the following: * Answer questions about their medical history and balance. * Do some standing and walking tests. Some of the tests will be timed. * Attend study visits and participate in study phone calls. * Keep track of any falls and notify study staff if they fall. * Wear the Walkasins device on a regular basis.

Interventions

  • DEVICE Walkasins
  • OTHER Fall Prevention Training

Study Locations (6)

Arizona

  • OrthoArizona--Mesa Arbor Avenue — Mesa

Massachusetts

  • Marcus Institute for Aging Research, Hebrew SeniorLife — Boston

Minnesota

  • Fairview Frontiers — Saint Paul

New York

  • Dent Neurologic Institute — Amherst

Pennsylvania

  • University of Pittsburgh — Pittsburgh

Texas

  • University of Texas Medical Branch — Galveston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-06-17
Est. Completion 2027-12-31
Phase NA

Sponsor

RxFunction

30 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06959277

The ClinicalTrials.gov registry entry for NCT06959277 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RxFunction, which has 30 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 5 conditions, with Peripheral Neuropathy Due to Chemotherapy appearing as the primary indexed condition, and to 2 interventions — of which Walkasins is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06959277 reports 6 study locations spanning 6 distinct geographic areas — top geographies include Arizona, Massachusetts, Minnesota. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06959277 about?

NCT06959277 is a clinical study titled "Balance4Mobility: Effects of Walkasins Use in Individuals With Peripheral Neuropathy and Balance Problems". The goal of this clinical trial is to is to test whether Walkasins can help people with peripheral neuropathy maintain their balance better. The main question it aims to answer is whether participants who use Walkasins on an everyday basis over a six-month period will report better awareness of thei...

What is the current status of trial NCT06959277?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2025-06-17. Estimated completion is 2027-12-31.

What conditions does trial NCT06959277 study?

This clinical trial studies the following conditions: Peripheral Neuropathy Due to Chemotherapy, Peripheral Neuropathies, Peripheral Neuropathy With Type 2 Diabetes, Balance Control in Elderly, Gait Disorders. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06959277?

The interventions under investigation include: Walkasins (DEVICE), Fall Prevention Training (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06959277?

This trial is sponsored by RxFunction, which has 30 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06959277 being conducted?

This trial has 6 study locations across Arizona, Massachusetts, Minnesota, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial